168 related articles for article (PubMed ID: 8962118)
1. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.
Röpke M; Hald J; Guldberg P; Zeuthen J; Nørgaard L; Fugger L; Svejgaard A; Van der Burg S; Nijman HW; Melief CJ; Claesson MH
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14704-7. PubMed ID: 8962118
[TBL] [Abstract][Full Text] [Related]
2. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
[TBL] [Abstract][Full Text] [Related]
3. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
4. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.
Barfoed AM; Petersen TR; Kirkin AF; Thor Straten P; Claesson MH; Zeuthen J
Scand J Immunol; 2000 Feb; 51(2):128-33. PubMed ID: 10652158
[TBL] [Abstract][Full Text] [Related]
6. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
7. CD4+ T helper responses in squamous cell carcinoma of the head and neck.
Chikamatsu K; Sakakura K; Yamamoto T; Furuya N; Whiteside TL; Masuyama K
Oral Oncol; 2008 Sep; 44(9):870-7. PubMed ID: 18221909
[TBL] [Abstract][Full Text] [Related]
8. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.
Chikamatsu K; Nakano K; Storkus WJ; Appella E; Lotze MT; Whiteside TL; DeLeo AB
Clin Cancer Res; 1999 Jun; 5(6):1281-8. PubMed ID: 10389910
[TBL] [Abstract][Full Text] [Related]
9. p53 as an immunotherapeutic target in head and neck cancer.
Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
[TBL] [Abstract][Full Text] [Related]
10. Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer.
Albers AE; Qian X; Kaufmann AM; Mytilineos D; Ferris RL; Hoffmann TK; DeLeo AB
Sci Rep; 2018 Jul; 8(1):10716. PubMed ID: 30013227
[TBL] [Abstract][Full Text] [Related]
11. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.
McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK
Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas.
Gnjatic S; Cai Z; Viguier M; Chouaib S; Guillet JG; Choppin J
J Immunol; 1998 Jan; 160(1):328-33. PubMed ID: 9551988
[TBL] [Abstract][Full Text] [Related]
13. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674
[TBL] [Abstract][Full Text] [Related]
14. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope.
Würtzen PA; Claesson MH
Int J Cancer; 2002 Jun; 99(4):568-72. PubMed ID: 11992547
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.
Nikitina EY; Clark JI; Van Beynen J; Chada S; Virmani AK; Carbone DP; Gabrilovich DI
Clin Cancer Res; 2001 Jan; 7(1):127-35. PubMed ID: 11205900
[TBL] [Abstract][Full Text] [Related]
16. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
[TBL] [Abstract][Full Text] [Related]
17. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.
Yu Z; Liu X; McCarty TM; Diamond DJ; Ellenhorn JD
J Surg Res; 1997 May; 69(2):337-43. PubMed ID: 9224403
[TBL] [Abstract][Full Text] [Related]
18. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.
Houbiers JG; Nijman HW; van der Burg SH; Drijfhout JW; Kenemans P; van de Velde CJ; Brand A; Momburg F; Kast WM; Melief CJ
Eur J Immunol; 1993 Sep; 23(9):2072-7. PubMed ID: 8370389
[TBL] [Abstract][Full Text] [Related]
19. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
[TBL] [Abstract][Full Text] [Related]
20. Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice.
Petersen TR; Bregenholta S; Pedersen LO; Nissen MH; Claesson MH
Cancer Lett; 1999 Apr; 137(2):183-91. PubMed ID: 10374840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
